Reuters
J&J vaccine adds to COVID-19 armoury, includes South African variant
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants, giving health officials another weapon to tackle the pandemic. In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread. The data showed that the vaccine’s effect on the South Africa variant was diminished compared to the unaltered virus, but infectious disease and public health experts said it can still help contain the virus spread and prevent deaths.